Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 484 participants.

Also called NCT06096337

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 484 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06096337
Other papers using this trial's data
  • Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation The New England journal of medicine, 2026-06-25 DOI, PubMed 42041224

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Austria, Belgium, Canada, Croatia, France, Germany, Hong Kong SAR China, Italy, Singapore, Spain, Taiwan (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06096337. Randomized; no masking; primary purpose treatment. Start 2023-12-28 (actual); primary completion 2026-02-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
Acronym
AVANT GUARD
Condition
Persistent Atrial Fibrillation
Intervention (Device)
FARAPULSE™ Pulsed Field Ablation (PFA) System
Intervention (Drug)
Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct06096337
Content hash
6b30c2d668c651ad77aa46cb15ddffe8fab8fd7bd61d075bdb13223ba110c9a6